Published on: May 2022
Why is there a demand for FGF-2 Inhibitors in the market?
The need for receptor tyrosine kinase inhibitors has increased significantly in recent years, since various studies have shown that these receptors play a critical part in the regulation of proper cell growth and division. Fibroblast growth factor receptors are one of the most common tyrosine kinase receptors found in normal cells, and mutations in this receptor have been linked to cancer start and progression. FGFR inhibitors are a new family of medications that can target EGFR-mutated tumours, and this approach has the potential to replace a variety of established and novel cancer treatments.
It’s all in the history of FGF-2 Inhibitors
Following the approval of the first medicine in this class in 2019, a number of major pharmaceutical and biotech companies have begun to view this strategy as one of the best treatments for a variety of cancers. Balversa, Pemazyre, and Truseltiq are three FGFR inhibitor medications currently on the market that are suggested for the treatment of urothelial cancer and cholangiocarcinoma. The adoption of these commercially available FGFR inhibitors points to the segment's future market potential, and many more FGFR inhibitor candidates are expected to be approved in the coming years. Balversa is a Janssen Pharmaceuticals medication that is now being researched for use in the treatment of different cancers such as prostate cancer, lymphoma, and other solid tumours. Pemazyre is also a product of Incyte Corporation, and it is proving therapeutic efficacy in the management of several major malignancies, both as monotherapy and in combination. Trusletiq, for example, is a BridgeBio pharma product that was recently approved in the United States and has shown potential to cure a variety of tumours in clinical trials.
Has the covid-19 pandemic affected the predicted growth of FGF-2 Inhibitors?
Pemazyre is also the only FGFR inhibitor medicine accessible outside of the United States. By the end of next year, several medications in this class are projected to gain clearance in other emerging markets. Over the next several years, the therapy and related market are expected to have a significant impact on improving overall survival and cancer recurrence rates, both of which are regarded key market drivers. In addition, the healthcare sectors of leading countries are encouraging manufacturers to produce novel classes in order to improve cancer survival rates. By the end of 2026, the global market for FGFR inhibitors is expected to surpass US$ 4 billion, and it will hold a market share of 4%.
Don’t just scrape the top of the cake, eat the entire cake. Get your hands on the expert report from the Market Insights Report's. <hyperlink>